April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Progression of visual field in patients with primary open-angle glaucoma: The Study PROG-F 2 . Levels of progression
Author Affiliations & Notes
  • Jean-Marie Giraud
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
    Ophthalmology, Val de Grâce Military Hospital, Paris, France
  • Florent Aptel
    Ophthalmology, Grenoble University Hospital, Grenoble, France
  • Hussam El Chehab
    Ophthalmology, Val de Grâce Military Hospital, Paris, France
  • Nischal Aryal-Charles
    Ophthalmology, Grenoble University Hospital, Grenoble, France
  • Maxime Delbarre
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
  • Bernard Valero
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
  • Rim Sekfali
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
  • Marie Bourniquel
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
  • Rodolphe Vignal
    Ophthalmology, Sainte Anne Military Hospital, Toulon, France
  • Jean-Paul G Renard
    Ophthalmology, Val de Grâce Military Hospital, Paris, France
  • Footnotes
    Commercial Relationships Jean-Marie Giraud, None; Florent Aptel, None; Hussam El Chehab, None; Nischal Aryal-Charles, None; Maxime Delbarre, None; Bernard Valero, None; Rim Sekfali, None; Marie Bourniquel, None; Rodolphe Vignal, None; Jean-Paul Renard, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5617. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jean-Marie Giraud, Florent Aptel, Hussam El Chehab, Nischal Aryal-Charles, Maxime Delbarre, Bernard Valero, Rim Sekfali, Marie Bourniquel, Rodolphe Vignal, Jean-Paul G Renard; Progression of visual field in patients with primary open-angle glaucoma: The Study PROG-F 2 . Levels of progression. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5617.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

From a multicentric database, to analyze Mean Deviation (MD) and Visual Field Index (VFI) rates of progression, of non evolutive and evolutive patients with treated ocular hypertension (OHT) or primary-open angle glaucoma (POAG).

 
Methods
 

441 eyes of 228 patients with treated OHT or POAG followed up at least 5 years (mean=8.4 years) with Humphrey 24.2 Sita-Standard VF exam at least twice a year were identified and classified in 5 groups: 104 OHT, 205 early glaucoma (MD>-6dB), 45 moderate glaucoma (MD-6 to -12dB), 41 advanced glaucoma (MD-12 to -18dB) and 46 severe glaucoma (MD<-18dB). With final datas, patients were classified in 2 sub groups: “evolutive” or “stable” patients if worsening or not to upper grade. Rate of progression during follow-up period was calculated using the trend analysis of the Guided Progression Analysis software.

 
Results
 

See table below

 
Conclusions
 

MD and VFI progression rates are clearly lower in OHT (‘stable’ and ‘evolutive’) groups than in POAG. In early, moderate and advanced POAG, supposed ‘stable’ patients, MD progression rate is around -0.1dB/year, similar to results of prior published studies with smaller populations. In the 3 supposed ‘evolutive’ patients subgroups, MD rates of progression are very close, with a significant difference from ‘stable’ populations. VFI’s progression rates are higher in the most advanced grades of POAG. Patients categorised in high grades of glaucoma at inclusion in the study may have a quicker progression In OHT, patients with progression rate higher than -0.28dB/year for MD or -0.41%/year for VFI have big risk to progress to glaucoma. In glaucoma patients, progression rates higher at -0.8dB/year for MD, -2.5%/year for VFI could be good marker of evolutive glaucoma.

  
Keywords: 758 visual fields • 642 perimetry  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×